El Mata Callos

Description

No description information is available for the specified drug.

Uses and Indications

This drug is indicated for the removal of warts.

There are no teratogenic effects associated with this drug. Additionally, no nonteratogenic effects have been reported.

Dosage and Administration

The affected area should be washed thoroughly prior to application. For optimal results, the wart may be soaked in warm water for approximately 5 minutes. After soaking, the area must be dried completely. It is recommended to gently smooth the surface of the wart before application.

A small amount of the product should be applied to sufficiently cover each wart. After application, the area should be allowed to dry. This procedure may be repeated once or twice daily as needed, continuing until the wart is removed, for a maximum duration of 12 weeks.

Healthcare professionals are advised to supervise the use of this product in children to ensure proper application and safety.

Contraindications

Use is contraindicated in the following situations:

• Application on irritated skin is prohibited due to the potential for exacerbating the condition.

• Do not apply to any area that is infected or reddened, as this may worsen the infection or inflammation.

• The product should not be used by individuals with diabetes or poor blood circulation, as these conditions may increase the risk of adverse effects.

• Avoid use on moles, birthmarks, warts with hair growing from them, genital warts, or mucous membranes to prevent potential complications or irritation.

Warnings and Precautions

For external use only. In the event of contact with the eyes, it is imperative to flush the eyes with water for a minimum of 15 minutes. Inhalation of vapors should be avoided to prevent respiratory irritation.

General precautions must be observed to ensure safe use of the product. It should not be applied to irritated skin or any area that appears infected or reddened. Individuals with diabetes or those who exhibit poor blood circulation should refrain from using this product. Additionally, it is contraindicated for application on moles, birthmarks, warts with hair growth, genital warts, or mucous membranes.

In the case of an overdose, immediate medical assistance should be sought, or a Poison Control Center should be contacted without delay to ensure appropriate management.

Healthcare professionals are advised to monitor patients for any adverse reactions and to provide guidance on the safe use of this product, emphasizing the importance of adhering to the outlined precautions.

Side Effects

Patients should be aware that the product is intended for external use only. In the event that the product comes into contact with the eyes, it is crucial to flush the eyes with water for at least 15 minutes to mitigate potential irritation. Additionally, patients are advised to avoid inhaling vapors associated with the product, as this may lead to adverse respiratory effects.

These warnings highlight the importance of proper usage and handling to prevent serious reactions. It is essential for patients to follow these guidelines to ensure their safety while using the product.

Drug Interactions

There are currently no documented drug interactions associated with this medication. Additionally, there is no information available regarding interactions with laboratory tests. As such, no specific recommendations for dosage adjustments or monitoring are warranted at this time.

Packaging & NDC

Below are the non-prescription pack sizes of El Mata Callos (salicylic acid). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients should be supervised during the use of this product to ensure safety and proper administration. Caregivers are advised to monitor children closely while using the medication to mitigate any potential risks associated with its use.

Geriatric Use

There is no specific information regarding the use of this medication in geriatric patients, including dosage adjustments, safety concerns, or special precautions. Healthcare providers should exercise caution when prescribing this medication to elderly patients, as individual responses may vary. Monitoring for potential adverse effects and therapeutic efficacy is recommended in this population.

Pregnancy

Pregnant patients and those who are breastfeeding should consult a healthcare professional prior to using this medication. It is important to assess the potential risks and benefits, as well as any available data regarding fetal outcomes and breastfeeding safety. Healthcare providers should consider individual circumstances and the specific health needs of the patient when making recommendations.

Lactation

Lactating mothers are advised to consult a health professional prior to using this medication. There is currently no available data on the excretion of this drug in human breast milk or its effects on breastfed infants. Therefore, caution is recommended when administering this medication to lactating individuals.

Renal Impairment

There is no information available regarding renal impairment, including dosage adjustments, special monitoring, or safety considerations for patients with reduced kidney function. Healthcare professionals should exercise caution and consider the lack of specific guidance when treating patients with renal impairment.

Hepatic Impairment

There is no information available regarding the use of this medication in patients with hepatic impairment. Consequently, there are no dosage adjustments, special monitoring requirements, or precautions specified for individuals with compromised liver function. Healthcare professionals should exercise clinical judgment when considering the use of this medication in patients with liver problems, as the absence of specific guidance necessitates careful evaluation of the potential risks and benefits.

Overdosage

There is currently no specific information available regarding overdosage for this medication. In the absence of documented overdosage data, healthcare professionals are advised to exercise caution and monitor patients closely for any unusual symptoms or adverse effects that may arise following administration.

In the event of suspected overdosage, it is recommended that healthcare providers initiate supportive care and symptomatic treatment as necessary. Continuous monitoring of vital signs and clinical status is essential to ensure patient safety.

Healthcare professionals should also consider consulting a poison control center or relevant toxicology resources for guidance on management strategies tailored to the specific circumstances of the overdosage event.

Nonclinical Toxicology

There are no teratogenic effects observed in the nonclinical studies conducted. Additionally, no non-teratogenic effects have been reported. The available data does not indicate any findings related to animal pharmacology and toxicology.

Postmarketing Experience

No postmarketing experience details are available in the insert text.

Patient Counseling

Healthcare providers should advise patients to keep this medication out of reach of children to prevent accidental ingestion. In the event of an overdose, patients should be instructed to seek medical help immediately or contact a Poison Control Center for assistance. It is essential for patients to understand the importance of these precautions to ensure their safety and the safety of others.

Storage and Handling

The product is supplied in various package configurations, with specific NDC numbers available for identification. It is essential to store the product at a controlled room temperature, maintaining a range of 15-30°C (59-86°F). Proper storage conditions are crucial to ensure the integrity and efficacy of the product.

Additional Clinical Information

No further data are available.

Drug Information (PDF)

This file contains official product information for El Mata Callos, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)